Progress of uroacitides in hematological system diseases
10.3760/cma.j.issn.1009-9921.2019.10.016
- VernacularTitle: 尿多酸肽在血液系统疾病中的研究进展
- Author:
Honggang CAO
1
,
2
;
Jingyun SHI
3
;
Tao WU
1
;
Hai BAI
1
Author Information
1. Department of Hematology, Lanzhou General Hospital, Lanzhou Command, Lanzhou 730050, China
2. Cao Honggang is Working on the Health Center of Beichengpu Town in Tongwei County of Gansu Province, Dingxi 743323, China
3. Department of Neonatology, Gansu Provincial Maternity and Child-Care Hospital, Lanzhou 730050, China
- Publication Type:Review
- Keywords:
Myelodysplastic syndromes;
Multiple myeloma;
Antineoplastic agents;
Hematologic neoplasms;
Uroacitide
- From:
Journal of Leukemia & Lymphoma
2019;28(10):637-640
- CountryChina
- Language:Chinese
-
Abstract:
Uroacitide is a new anti-tumor drug, which is extracted from non-cytotoxic urine of the healthy human urine. In recent years, there have been many basic experiments and clinical trials focusing on its role in hematological diseases, especially in the treatment of myelodysplastic syndromes (MDS). There are also some basic researches on the treatment of other hematological diseases, which lays a foundation for further expanding its clinical indications and opens up a new way for the treatment of hematological diseases.
